Ursodeoxycholic Acid Market Size by Type, Application, Manufacturing, Dosage Form, End User and Forecast 2034
Overview
The Global Ursodeoxycholic Acid Market size was valued at USD 600 Million in 2025 and is projected to grow at a CAGR of 10.62% from 2025 to 2034, reaching USD 1,488.18 Million by 2034.
Ursodeoxycholic Acid Market Overview
Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid that has become a standard therapy for managing cholesterol gallstones and, more significantly, for treating primary biliary cholangitis (PBC), a chronic liver condition in which UDCA continues to serve as the first-line treatment of choice. The market's steady growth is largely explained by a few consistent factors: an ageing global population, a rising number of diagnosed liver and gallbladder cases, and clinical guidelines that have not identified a reason to move away from UDCA as the preferred therapy. This keeps demand stable across pharmaceutical companies, hospitals, specialty pharmacies, and hepatology clinics, particularly across North America. On the manufacturing side, production is also becoming more efficient, with chicken-bile-derived processes and enzymatic synthesis routes allowing API manufacturers to produce UDCA faster, with lower costs and reduced environmental impact compared to conventional chemical synthesis methods.
Ursodeoxycholic acid market report provides a comprehensive analysis of the Global Ursodeoxycholic Acid Market, covering the current market landscape, key growth drivers, emerging trends, market dynamics, segmentation, regional opportunities, competitive developments, and leading industry players. It examines the market across its full value chain, from raw-material sourcing and API manufacturing through to formulation and distribution, while assessing the impact of evolving PBC treatment protocols, manufacturing advancements, and shifting healthcare priorities. The report further presents detailed market size estimates, share data, and growth projections through 2034, highlighting the key opportunities expected to shape the future of the global UDCA market.
| “The Ursodeoxycholic Acid Market is more than a pharmaceutical molecule—it is a story of trusted therapy, evolving manufacturing, and expanding access to liver care. This report looks beyond the numbers to understand where the market is heading, where opportunities are emerging, and what could shape its next chapter.”
- Mrunal Chikte |
Ursodeoxycholic Acid Market Key Highlights
• The Global Ursodeoxycholic Acid Market size was valued at USD 620.10 Million in 2025 and is expected to reach USD 1,488.18 Million by 2034, growing at a CAGR of 10.62% during the forecast period.
• Growing adoption of combination therapies pairing UDCA with newer second-line agents is reinforcing its role as the clinical backbone of cholestatic liver disease treatment, rather than displacing its demand.
• The Ursodeoxycholic acid market is transitioning from a purely cost-driven generic business toward one shaped by GMP compliance, production efficiency, formulation innovation, and secure raw-material sourcing.
Global Ursodeoxycholic Acid Market Size and Forecast
To know about the Research Methodology :- Request Free Sample Report
Ursodeoxycholic Acid Market Dynamics:
Growing Prevalence and Diagnosis of Hepatobiliary Disorders to Drive Ursodeoxycholic Acid Market Growth
The growing prevalence and diagnosis of hepatobiliary disorders, particularly Primary Biliary Cholangitis (PBC), is driving demand for ursodeoxycholic acid (UDCA) worldwide. UDCA remains a standard first-line therapy for PBC, with long-term treatment recommended for patients who tolerate it. Rising healthcare awareness, improved diagnosis, and continued use of UDCA alongside newer second-line therapies are further supporting market growth.
Intense Generic Competition and Production Costs to Restraints the Ursodeoxycholic Acid Market
Generic competition remains one of the most significant pressures on the Ursodeoxycholic Acid Market. The top five API manufacturers currently control close to 81% of global UDCA supply, and this concentration pushes smaller formulators into tender-based pricing battles where margins are already thin. Because production still depends heavily on bile-derived raw materials, sourcing costs can fluctuate sharply whenever supply from bovine or chicken-bile extraction is disrupted. On top of that, meeting FDA, EMA, and other regional GMP and Drug Master File requirements adds meaningful compliance overhead, a cost burden that mid-sized and smaller manufacturers absorb far less easily than the handful of vertically integrated players who dominate the category.
Generic Competition and Raw-Material Dependence Create Challenges for the Ursodeoxycholic Acid Market
The global Ursodeoxycholic Acid production due to its cost and scalability advantages, price competition among generic manufacturers continues to intensify, gradually compressing profit margins across the industry. This is compounded by the market's reliance on a narrow raw-material base since roughly four out of every five units of API supply comes from just five producers, any disruption in bile-derived sourcing can quickly affect pricing and availability downstream. Regulatory and GMP compliance costs add a further layer of pressure, particularly for manufacturers without the scale to spread these costs across large production volumes.
Market Trends – Ursodeoxycholic Acid Market
Ursodeoxycholic Acid Market Segment Analysis
Ursodeoxycholic Acid Market, By Dosage Form
The tablets segment held the largest share of the global ursodeoxycholic acid market in 2025. Its strong position is supported by widespread prescription use, established manufacturing capabilities, convenient oral administration, and the availability of commonly used 250 mg and 500 mg strengths. Ursodiol tablets are widely used in the management of primary biliary cholangitis and are generally administered in divided doses, supporting their continued adoption for long-term treatment. Capsules account for about 22% of the market, supported by their availability in commonly prescribed strengths such as 300 mg and their convenience for patients requiring regular oral therapy. Oral suspensions represent approximately 6% of the market, primarily catering to pediatric patients and individuals who experience difficulty swallowing tablets or capsules. Overall, the continued preference for convenient and established solid oral formulations is expected to keep tablets and capsules as the dominant dosage forms throughout the forecast period.
Ursodeoxycholic Acid Market, by Manufacturing Type
The Global Ursodeoxycholic Acid (UDCA) Market is segmented into Bile-Derived/Extraction-Based Production, Synthetic Production, Semi-Synthetic Production, and Enzymatic Production. In 2025, Synthetic Production is expected to dominate the market, supported by consistent quality, scalable manufacturing, pharmaceutical-grade purity, and reliable supply for UDCA-based medicines. Synthetic and semi-synthetic routes also offer manufacturers greater control over production efficiency and product specifications, while bile-derived and enzymatic production continue to serve specific applications. The manufacturing landscape is expected to evolve during 2026–2034 as companies adopt advanced purification, process optimization, and enzymatic technologies to improve cost efficiency, production capacity, and supply reliability.
Ursodeoxycholic Acid Manufacturing Routes
Global Ursodeoxycholic Acid Market Regional Insights
North America — Leading Market Supported by Established Hepatology Care
North America dominated Ursodeoxycholic Acid Market in 2025, supported by advanced healthcare infrastructure, established diagnosis of hepatobiliary disorders, specialty-care facilities, and strong pharmaceutical distribution networks. Continued UDCA use in Primary Biliary Cholangitis (PBC) and the availability of branded and generic products support regional demand. The United States leads among individual countries in spending on ursodeoxycholic acid, supported by its high healthcare spending and the growing diagnosis and treatment of liver-related diseases. In North America, approximately 700,000 to 1 million people are actively prescribed Ursodeoxycholic Acid each year.
Key opportunity: Advanced hepatology care, established PBC treatment, specialty pharmacies, and combination therapies.
Europe — Established Pharmaceutical and Regulatory Ecosystem
Europe remains an important UDCA market, supported by its advanced pharmaceutical industry, specialist liver-care infrastructure, and strong GMP and regulatory standards. Established PBC treatment, UDCA availability, and a strong API and finished-dose manufacturing base continue to support regional growth. In Europe, approximately 800,000 to 1 million people are actively prescribed Ursodeoxycholic Acid (UDCA) annually.
Asia-Pacific — Manufacturing Expansion and Rising Healthcare Access
Asia-Pacific is the fastest-growing UDCA market, driven by expanding pharmaceutical manufacturing, rising healthcare expenditure, improved diagnosis, and growing access to generic medicines. China and India are key for API production, while Japan and South Korea support advanced pharmaceutical capabilities and manufacturing innovation. In the Asia-Pacific (APAC) region, approximately 1.2 million to 1.5 million people are actively prescribed Ursodeoxycholic Acid (UDCA) each year.
Key opportunity: API manufacturing, capacity expansion, cost-efficient production, healthcare access, and emerging-market demand.
Global Ursodeoxycholic Acid Market Competitive Landscape
The API and generic pharmaceutical business are evolving into a more integrated industry, where manufacturing efficiency, supply security, and formulation quality now carry as much weight as pricing. Competitive differentiation is increasingly built around API purity, GMP compliance, secure access to raw materials, production capacity, and the ability to serve markets across multiple regions. While several manufacturers continue to rely on traditional bile-derived extraction, others have transitioned to synthetic or semi-synthetic production routes. Companies gaining the strongest market position are those exercising greater control over their own sourcing and manufacturing, rather than depending on third-party suppliers.
Ursodeoxycholic Acid Market leaders invest in advanced purification technology, expand GMP-compliant production capacity, and maintain reliable global distribution. Manufacturers producing tablets, capsules, and oral suspensions have a meaningful opportunity to differentiate through product quality and patient-centric formulation development. As treatment approaches for conditions such as PBC continue to advance, companies that combine consistent quality, cost-efficient production, regulatory compliance, secure raw-material sourcing, and strong global reach are best positioned to strengthen their standing through capacity expansion, technological innovation, and strategic partnerships.
Global Ursodeoxycholic Acid Market Scope: Inquire before buying
| Ursodeoxycholic Acid Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 600 Mn. |
| Forecast Period 2026 to 2034 CAGR: | 10.62% | Market Size in 2034: | USD 1,488.18 Mn. |
| Segments Covered: | by Manufacturing | Chemical Production Bile-Derived/Semi-Synthetic Production Enzymatic/Biosynthetic Production Other Emerging Production Routes |
|
| by Dosage Form | Tablets Capsules Oral Suspensions |
||
| by Application | Primary Biliary Cholangitis (PBC) Dissolution and Prophylaxis Cholestatic Liver Diseases Primary Sclerosing Cholangitis (PSC) Other Hepatobiliary Disorders |
||
| by End-Use Industry | Hospitals Specialty Clinics Home Care Other End Users |
||
Global Ursodeoxycholic Acid Market By region:
North America (United States ,Canada and Mexico)
Europe (United Kingdom, France, Germany, Italy ,Spain ,Sweden ,Russia ,Rest of Europe)
Asia Pacific ( China, South Korea, India, Japan, Australia ,Indonesia, Philippines ,Malaysia Vietnam, Thailand, Rest of Asia Pacific)
Middle East and Africa (Saudi Arabia, United Arab Emirates (UAE), Qatar Kuwait Oman Bahrain, Rest of ME&A)
South America (Brazil, Argentina, Chile, Colombia, Rest of South America)
Global Ursodeoxycholic Acid key players:
North America
1. Abbott Laboratories
2. Teva Pharmaceutical Industries Ltd.
3. Viatris Inc.
4. Amneal Pharmaceuticals, Inc.
5. Apotex Inc.
6. Epic Pharma, LLC
Europe
7. ICE Pharma S.p.A.
8. JSC Grindeks
9. Dipharma Francis S.r.l.
10. Axplora
11. PharmaZell GmbH
12. Dr. Falk Pharma GmbH
13. Bruschettini S.r.l.
14. Erregierre S.p.A.
Asia-Pacific
15. Daewoong Pharmaceutical Co., Ltd.
16. Mitsubishi Tanabe Pharma Corporation
17. Glenmark Pharmaceuticals Ltd.
18. Sun Pharmaceutical Industries Ltd.
19. Cipla Ltd.
20. Lupin Ltd.
21. Mankind Pharma Ltd.
22. Aurobindo Pharma Ltd.
23. Arch Pharmalabs Ltd.
24. Kimia Biosciences Ltd.
25. Suzhou Tianlu Bio-Pharmaceutical Co., Ltd.
26. Zhongshan Belling Biotechnology Co., Ltd.
South America
27. Eurofarma Laboratórios S.A.
28. EMS S.A.
29. Hypera Pharma
30. Laboratorios Roemmers
31. Bagó
Middle East & Africa
32. Julphar (Gulf Pharmaceutical Industries)
33. Tabuk Pharmaceuticals
34. Hikma Pharmaceuticals
35. Aspen Pharmacare
36. Jamjoom Pharma
Frequently Asked Questions
1)What is the size of the Global Ursodeoxycholic Acid Market?
The global Ursodeoxycholic Acid market was valued at USD 600 million in 2025 and is expected to reach around USD 1,488.18 million by 2034, growing at an estimated CAGR of 10.62% during the forecast period
2)Which segment includes the Global Ursodeoxycholic Acid Market?
The Primary Biliary Cholangitis (PBC) segment is expected to hold a dominant position by application, supported by the continued use of UDCA as an established first-line treatment for PBC. By dosage form, Tablets represent a major segment due to their widespread use, convenient administration, and availability across generic pharmaceutical markets.
3)Which region held the largest share of the Global Ursodeoxycholic Acid Market in 2025?
North America is maintaining a leading position during the forecast period, supported by advanced healthcare infrastructure, established hepatology services, high diagnosis rates, and strong access to prescription medicines and specialty pharmacy networks.
4)What are the major trends shaping the Global Ursodeoxycholic Acid Market?
Major trends include UDCA API capacity expansion, vertical integration of raw-material sourcing and manufacturing, advanced extraction and purification technologies, combination therapies for PBC, patient-friendly oral formulations, digitalized pharmaceutical manufacturing, and increasing focus on sustainable production practices.